GSK256066 Trifluoroacetate (GSK256066; GSK-256066), the trifluoroacetic acid salt form of GSK256066, is a novel selective inhibitor of PDE4B (phosphodiesterase 4B) with important biological activity (e.g. inhibiting pulmonary neutrophilia) and thus has the potential to be used for treatment for chronic obstructive pulmonary disease.

Vardenafil HCl, also known as BAY 38-9456 HCl, is a novel and potent PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

m-3M3FBS is a novel and potent activator of phospholipase C (PLC).

THPP-1 is a novel, potent and orally bioavailable PDE10A (phosphodiesterase 10A) inhibitor with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively.

W-7 HCl is a novel, potent and selective calmodulin antagonist with antitumor activity.

MY-5445 is a potent inhibitor of platelet aggregatio.

Flavoxate is an anticholinergic (AChR) agent that binds and inhibits muscarinic receptors, thereby suppressing the micturition reflex and increases urinary bladder capacity by modifying the micturition center in the brain stem.

BI 409306 (SUB 166499) is a novel potent, selective and oral phosphodiesterase 9A (PDE9A) inhibitor.

Ro20-1724 (Ro-201724) is a novel and potent inhibitor of cyclic nucleotide phosphodiesterase with neuroprotective effects. It shows selectivity for PDE4.

PF-05085727 (PF05085727) is a novel, highly potent, selective and brain penetrant Phosphodiesterase 2A (PDE2A) inhibitor (IC50 = 2 nM) with the potential to be used for cognition disorders.